Abstract
Overview
Introduction
Novel pipeline drugs, lifecycle management of the current branded
antidepressants, and development of atypical antipsychotics for depression are
set to grow the depression market through to 2010 when it will peak at $14.6
billion. Thereafter, however, generic incursion of the atypical antipsychotics
and the remaining branded antidepressants will see the depression market value
drop to 2016.
Scope
- This report focuses on the leading pharmacotherapies used to treat
depression with sales and volume country- and indication-specific forecasts to
2016
- Assessment of current and future opportunities and threats in the
depression market across the seven major pharmaceutical markets
- Future market events that are expected to affect drug revenues are
discussed and quantified for each of the seven major markets
- Lifecycle management case studies show how previously successful
strategies should be applied in today' s market
Highlights
Sales of atypical antipsychotics in depression are set to be stimulated by
anticipated positive clinical trial data investigating the use of Seroquel
(quetiapine) in this indication. Datamonitor forecasts peak class level seven
major market sales of $1.43 billion in 2008, followed by a decline due to
competition from pipeline drugs and generics.
Timing of launch of Wyeth' s reformulation Pristiq (desvenlafaxine) would
appear to be optimal. However, no evidence exists to indicate that it is an
improvement over the parent compound Effexor (venlafaxine). By focusing
Pristiq on a niche cohort of depressed patients, Wyeth has done enough to
diversify Pristiq to ensure moderate success.
The introduction of newer generation antidepressants such as the SNRIs Effexor
and Cymbalta (duloxetine) and the SSRI Lexapro (escitalopram) into the
Japanese depression market will drive its value considerably, resulting in a
52% increase by 2012.
Reasons to Purchase
- Assess the impact of events such as patent expiries and new product
launches on the depression-specific sales of key marketed brands
- Quantify the future size of the depression market, in terms of volume and
value, in each of the seven major markets
- Identify key lifecycle management strategies that can ensure growth in the
competitive depression market
View Cart
